Table 4.
Univariate and multivariate analyses for factors affecting objective response in the low-alpha-fetoprotein group.
| Factors | Univaritate Analysis | Multivariate Analysis | |||||
|---|---|---|---|---|---|---|---|
| Odds Ratio | 95% CI | p-Value | Odds Ratio | 95% CI | p-Value | ||
| Sex (M/F) | 0.750 | 0.135–4.165 | 0.742 | ||||
| Age (<65 years/≥65 years) | 0.655 | 0.134–3.187 | 0.600 | ||||
| BW (<60 kg/≥60 kg) | 0.857 | 0.198–3.713 | 0.837 | ||||
| PS (0/1–) | 0.500 | 0.040–6.128 | 0.590 | ||||
| ALBI (<−2.44/≥−2.44) | 5.500 | 1.065–28.416 | 0.042 | 6.866 | 1.098–42.923 | 0.039 | |
| BCLC a A,B/C | 0.656 | −0.151–2.843 | 0.573 | ||||
| Tumor size (mm) (<30/≥30) | 0.667 | 0.153–2.903 | 0.589 | ||||
| Tumor number (<4/≥4) | 3.667 | 0.771–17.429 | 0.102 | ||||
| EHS absence/presence | 0.667 | 0.094–4.373 | 0.685 | ||||
| MVI absence/presence | 0.500 | 0.040–6.218 | 0.590 | ||||
| DCP (mAU/mL) (<40/≥40) | 0.256 | 0.048–1.282 | 0.098 | 0.191 | 0.029–1.266 | 0.086 | |
| AFP response b | 1.333 | 0.240–7.405 | 0.742 | ||||
| DCP response b | - | - | - | ||||
M, male; F, female; BW, body weight; PS, performance status; ALBI, albumin-bilirubin; MVI, macrovascular invasion; EHS, extrahepatic spread; AFP, alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin; CI, confidence interval; a BCLC, Barcelona Clinic Liver Cancer staging; b AFP and DCP responses were assessed after one months after lenvatinib induction; a positive response was defined as a reduction of ≥ 40% from baseline.